Evoke Pharma, Inc. (EVOK): Price and Financial Metrics


Evoke Pharma, Inc. (EVOK): $3.05

-0.10 (-3.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

EVOK Stock Summary

  • EVOK has a market capitalization of $16,096,854 -- more than approximately only 2.08% of US stocks.
  • As for revenue growth, note that EVOK's revenue has grown 6,929% over the past 12 months; that beats the revenue growth of 99.72% of US companies in our set.
  • Evoke Pharma Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -83.42%, greater than the shareholder yield of only 4.84% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Evoke Pharma Inc, a group of peers worth examining would be EBET, SGBX, EOSE, UAVS, and BLDE.
  • Visit EVOK's SEC page to see the company's official filings. To visit the company's web site, go to www.evokepharma.com.

EVOK Valuation Summary

  • EVOK's price/sales ratio is 108.6; this is 856.83% higher than that of the median Healthcare stock.
  • Over the past 97 months, EVOK's price/sales ratio has gone NA NA.
  • EVOK's price/sales ratio has moved NA NA over the prior 97 months.

Below are key valuation metrics over time for EVOK.

Stock Date P/S P/B P/E EV/EBIT
EVOK 2021-08-31 108.6 6.4 -4.1 -3.0
EVOK 2021-08-30 102.9 6.0 -3.9 -2.7
EVOK 2021-08-27 103.7 6.1 -3.9 -2.8
EVOK 2021-08-26 101.1 5.9 -3.8 -2.7
EVOK 2021-08-25 101.1 5.9 -3.8 -2.7
EVOK 2021-08-24 99.1 5.8 -3.7 -2.6

EVOK Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at 47.14%.
  • Its 5 year net income to common stockholders growth rate is now at 41.23%.
  • The 3 year net cashflow from operations growth rate now stands at 40.27%.
EVOK's revenue has moved up $1,618,076 over the prior 52 months.

The table below shows EVOK's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1.618076 -12.35294 -8.537952
2021-09-30 1.280525 -12.06725 -9.133452
2021-06-30 0.350076 -7.98564 -9.293105
2021-03-31 0.113441 -8.031231 -13.96986
2020-12-31 0.02302 -6.630007 -13.15467
2020-09-30 0 -6.066193 -12.30504

EVOK Price Target

For more insight on analysts targets of EVOK, see our EVOK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.50 Average Broker Recommendation 1.5 (Moderate Buy)

EVOK Stock Price Chart Interactive Chart >

Price chart for EVOK

EVOK Price/Volume Stats

Current price $3.05 52-week high $18.96
Prev. close $3.15 52-week low $2.03
Day low $3.02 Volume 40,800
Day high $3.14 Avg. volume 650,680
50-day MA $3.83 Dividend yield N/A
200-day MA $8.02 Market Cap 10.19M

Evoke Pharma, Inc. (EVOK) Company Bio


Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.


EVOK Latest News Stream


Event/Time News Detail
Loading, please wait...

EVOK Latest Social Stream


Loading social stream, please wait...

View Full EVOK Social Stream

Latest EVOK News From Around the Web

Below are the latest news stories about Evoke Pharma Inc that investors may wish to consider to help them evaluate EVOK as an investment opportunity.

Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease Week (DDW) May 2022

Revisiting the risk of tardive dyskinesia with metoclopramide use in diabetic gastroparesis: results of a real-world data driven epidemiology studySOLANA BEACH, Calif., and CHICAGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti (metoclopramide) nasal spray (GIMOTI), today announced that the results of a retrospective analysis of United States (US

Yahoo | February 24, 2022

GIMOTI® Commercialization Update

New Research Study Demonstrates Increased Acceptance Among Healthcare Providers Patient Testimonial Videos Detail Benefits Included and Available on GimotiRx.com Expanded Coverage with recent New York Medicaid Approval SOLANA BEACH, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced positive outcomes from an additional research study conducted for GIMOTI® (metocl

Yahoo | February 17, 2022

Evoke Pharma, Eversana extend commercialization contract for Gimoti

Evoke Pharma (EVOK +2.2%) and Eversana Life Science Services extended their agreement to continue collaborating on the commercialization and distribution of Gimoti (metoclopramide) nasal spray in the U.S. through the end of 2026. According to the original 2020 agreement, Evoke retains ownership of the Gimoti NDA and legal, regulatory, and manufacturing responsibilities...

Seeking Alpha | February 2, 2022

Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI

SOLANA BEACH, Calif. and CHICAGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseases, and EVERSANA Life Science Services, LLC, an independent provider of global commercial services to the life science industry, today announced the extension of their agreement to continue collaborating on the commercialization and distribution of Gimoti® (metoclopramide) nasal spray in the Unite

Yahoo | February 2, 2022

Evoke Pharma to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference

SOLANA BEACH, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (G.I.) diseases, today announced that the Company will participate in the H.C. Wainwright BIOCONNECT Conference occurring virtually on January 10 – 13, 2022. Management’s presentation will be available on the conference website beginning at 7:00 a.m. ET on January 10, 2022. Investors participating in the conference who

Yahoo | January 4, 2022

Read More 'EVOK' Stories Here

EVOK Price Returns

1-mo N/A
3-mo -48.65%
6-mo -53.79%
1-year -81.03%
3-year -59.33%
5-year -90.07%
YTD -53.79%
2021 -78.68%
2020 59.26%
2019 -34.68%
2018 9.73%
2017 11.88%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.478 seconds.